UNSPSC 51172141: Pramiverin or pramiverine

This classification denotes an antispasmotic agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 157NY06G9T, chemically known as 4,4-diphenyl-n-isopropylcyclohexylamine but generally known as pramiverin, which bears US NIH Compound Identifier 71681. European Medicines Agency schedules Pramiverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09992MIG.

The term PRAMIVERINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). Pramiverin or pramiverine bears US NLM identifiers UMLS ID C0663384 and NCI Concept Code C73175. SMILES: CC(C)NC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3.

UNSPSC 51172141 Pramiverin or pramiverine is a Commodity code that covers specific pharmaceutical active ingredients and their formulations for state and local health, correctional, and public-benefit procurement. Recent state and local activity under this code centers on specimen collection and drug testing services in correctional settings, pharmaceutical supply agreements for multi-state government health plans, and direct-to-manufacturer prescription fulfillment models for state health agencies. The issuing bodies soliciting under this code span state health and human services departments, county correctional supervision agencies, and multi-state cooperative purchasing alliances that aggregate demand across participating state and local entities. Work being solicited includes immunoassay and confirmatory drug screening (LC/MS/MS and GC/MS), collection-site staffing, oral-fluid and hair-testing methodologies, and pharmaceutical distribution through licensed wholesalers meeting SAMHSA and FDA compliance requirements.

Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a due date of July 23, 2026, and an estimated contract value of $600,000 over two years plus three optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission issued RFI No. HHS0017013 in late March 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. Recent activity clusters in Texas and the Upper Midwest, with demand driven by correctional agencies managing offender testing compliance and state health systems seeking cost-efficient pharmaceutical sourcing outside traditional pharmacy benefit manager arrangements.